Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma

被引:53
|
作者
Chung, Brian K. [1 ,2 ,3 ,4 ,5 ]
Karlsen, Tom Hemming [3 ,4 ,5 ,6 ]
Folseraas, Trine [3 ,4 ,5 ,6 ]
机构
[1] Univ Birmingham, Ctr Liver Res, Birmingham, W Midlands, England
[2] Univ Birmingham, Inst Immunol & Immunotherapy, NIHR Birmingham Inflammat Biomed Res Ctr, Birmingham, W Midlands, England
[3] Oslo Univ Hosp, Div Surg Inflammatory Med & Transplantat, Dept Transplantat Med, Norwegian PSC Res Ctr,Rikshosp, Postboks 4950, N-0424 Oslo, Norway
[4] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway
[5] Oslo Univ Hosp, Div Surg Inflammatory Med & Transplantat, Internal Med Res Inst, Rigshosp, Oslo, Norway
[6] Univ Oslo, Inst Clin Med, Fac Med, KG Jebsen Inflammat Res Ctr, Oslo, Norway
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2018年 / 1864卷 / 04期
关键词
Primary sclerosing cholangitis; Cholangiocytes; Cholangiocarcinoma; Pathogenesis; INDUCE CYCLOOXYGENASE-2 EXPRESSION; CANCER-ASSOCIATED FIBROBLASTS; PRIMARY BILIARY-CIRRHOSIS; ENDOTHELIAL GROWTH-FACTOR; GENOME-WIDE ASSOCIATION; NATURAL-HISTORY; BILE-ACIDS; RISK-FACTORS; DNA-DAMAGE; HEPATOCELLULAR-CARCINOMA;
D O I
10.1016/j.bbadis.2017.08.020
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Primary sclerosing cholangitis (PSC) is an idiopathic cholangiopathy strongly associated with inflammatory bowel disease (IBD) and characterized by cholestasis, chronic immune infiltration and progressive fibrosis of the intrahepatic and extrahepatic bile ducts. PSC confers a high risk of cholangiocarcinoma (CCA) with PSC-CCA representing the leading cause of PSC-associated mortality. PSC-CCA is derived from cholangiocytes and associated progenitor cells a heterogeneous group of dynamic epithelial cells lining the biliary tree that modulate the composition and volume of bile production by the liver. Infection, inflammation and cholestasis can trigger cholangiocyte activation leading to an increased expression of adhesion and antigen-presenting molecules as well as the release of various inflammatory and fibrogenic mediators. As a result, activated cholangiocytes engage in a myriad of cellular processes, including hepatocellular proliferation, apoptosis, angiogenesis and fibrosis. Cholangiocytes can also regulate the recruitment of immune cells, mesenchymal cells, and endothelial cells that participate in tissue repair and destruction in settings of persistent inflammation. In PSC, the role of cholangiocytes and the mechanisms governing their transformation to PSC-CCA are unclear however localization of disease suggests that cholangiocytes are a key target and potential regulator of hepatobiliary immunity, fibrogenesis and tumorigenesis. Herein, we summarize mechanisms of cholangiocyte activation in PSC and highlight new insights into disease pathways that may contribute to the development of PSC-CCA. This article is. part of a Special Issue entitled: Cholangiocytes in Health and Disease edited by Jesus Banales, Marco Marzioni, Nicholas LaRusso and Peter Jansen.
引用
收藏
页码:1390 / 1400
页数:11
相关论文
共 50 条
  • [21] Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review
    Song, Junmin
    Li, Yang
    Bowlus, Christopher L.
    Yang, GuoXiang
    Leung, Patrick S. C.
    Gershwin, M. Eric
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2020, 58 (01) : 134 - 149
  • [22] Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management
    Eaton, John E.
    Talwalkar, Jayant A.
    Lazaridis, Konstantinos N.
    Gores, Gregory J.
    Lindor, Keith D.
    GASTROENTEROLOGY, 2013, 145 (03) : 521 - 536
  • [23] Cholangiocytes and the environment in primary sclerosing cholangitis: where is the link?
    O'Hara, Steven P.
    Karlsen, Tom H.
    LaRusso, Nicholas F.
    GUT, 2017, 66 (11) : 1873 - 1877
  • [24] Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
    Cheung, Angela C.
    LaRusso, Nicholas F.
    Gores, Gregory J.
    Lazaridis, Konstantinos N.
    SEMINARS IN LIVER DISEASE, 2017, 37 (02) : 159 - 174
  • [25] Management of primary sclerosing cholangitis and its complications: an algorithmic approach
    Prokopic, Michal
    Beuers, Ulrich
    HEPATOLOGY INTERNATIONAL, 2021, 15 (01) : 6 - 20
  • [26] Predicting cholangiocarcinoma in primary sclerosing cholangitis: using artificial intelligence, clinical and laboratory data
    Chang Hu
    Ravishankar K. Iyer
    Brian D. Juran
    Bryan M. McCauley
    Elizabeth J. Atkinson
    John E. Eaton
    Ahmad H. Ali
    Konstantinos N. Lazaridis
    BMC Gastroenterology, 23
  • [27] Positron emission tomography and cholangiocarcinoma in primary sclerosing cholangitis
    Widjaja, A
    Mix, H
    Wagner, S
    Graz, KF
    van den Hoff, J
    Petrich, T
    Meier, PN
    Manns, MP
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 1999, 37 (08): : 731 - 733
  • [28] Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitis
    Fleming, KA
    Boberg, KM
    Glaumann, H
    Bergquist, A
    Smith, D
    Clausen, OPF
    JOURNAL OF HEPATOLOGY, 2001, 34 (03) : 360 - 365
  • [29] AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
    Bowlus, Christopher L.
    Arrive, Lionel
    Bergquist, Annika
    Deneau, Mark
    Forman, Lisa
    Ilyas, Sumera I.
    Lunsford, Keri E.
    Martinez, Mercedes
    Sapisochin, Gonzalo
    Shroff, Rachna
    Tabibian, James H.
    Assis, David N.
    HEPATOLOGY, 2023, 77 (02) : 659 - 702
  • [30] Pathogenesis and clinical spectrum of primary sclerosing cholangitis
    Neelam G Gidwaney
    Swati Pawa
    Kiron M Das
    World Journal of Gastroenterology, 2017, (14) : 2459 - 2469